Die medikamentöse Therapie der Patientin mit Endometriose

Subscribe to RSS DOI: 10.1055/s-0030-1271356 © Georg Thieme Verlag KG Stuttgart ˙ New York Die medikamentöse Therapie der Patientin mit Endometriose Publication History Publication Date: 09 March 2011 (online) Kernaussagen Finden sich endometriale Zellen außerhalb des Cavum uteri, resultiert eine Endometriose mit z. T. vielfältiger Beschwerdesymptomatik. Die Endometriose ist häufig chronisch und tritt mit einer Prävalenz von 4–30 % bei Frauen im gebärfähigen Alter auf; etwa die Hälfte der Frauen mit Fertilitätsproblematik ist davon betroffen. Aufgrund der Vielfalt der Symptome, die häufig weder mit dem Schweregrad noch mit der Lokalisation der Endometrioseläsionen korrelieren, steht die Laparoskopie mit histologischer Abklärung im Zentrum der Diagnostik. Als therapeutischer Goldstandard bei gesicherter Diagnose gilt die operative Entfernung der Endometrioseherde, ggf. prä- und postoperativ flankiert von einer medikamentösen Therapie. Unter Umständen kann auch eine alleinige medikamentöse Therapie erfolgen. Die medikamentösen Optionen zur Therapie der Endometriose werden mit folgender Zielsetzung eingesetzt: - Linderung der Schmerzen - Erhöhung der Schwangerschaftsraten - Reduktion der Rezidivraten Dies funktioniert meist nur in Kombination mit einer oder mehreren sanierenden Operationen. Vieles, wie die postoperative Rezidivprophylaxe oder die kontinuierliche Einnahme kombinierter Kontrazeptiva, ist durch prospektive randomisierte Vergleichstudien unzureichend belegt. Auch unter einer medikamentösen Rezidivprophylaxe nach sanierender „R0”-Operation ist die Neigung des Wiederauftretens der Beschwerden hoch. Literatur - 1 Knapp V J. How old is endometriosis? Late 17th- and 18th-century European descriptions of the disease. Fertil Steril. 1999; 72 10-14 - 2 Kiple K. The Cambridge world history of human disease.. Cambridge: Cambridge University Press; 1993 - 3 McGrew R. Encyclopedia of medical history.. New York: McGraw-Hill; 1985 - 4 Mahmood T A, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod. 1991; 6 544-549 - 5 Moen M H, Schei B. Epidemiology of endometriosis in a Norwegian county. Acta Obstet Gynecol Scand. 1997; 76 559-562 - 6 Vigano P et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004; 18 177-200 - 7 Witz C A, Burns W N. Endometriosis and infertility: is there a cause and effect relationship?. Gynecol Obstet Invest. 2002; 53 2-11 - 8 Simpson J L et al. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol. 1980; 137 327-331 - 9 Renner S P et al. Evaluation of clinical parameters and estrogen receptor alpha gene polymorphisms for patients with endometriosis. Reproduction. 2006; 131 153-161 - 10 Sallam H et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006 CD004635 - 11 Walter A J et al. Endometriosis: correlation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol. 2001; 184 1407-1411 discussion 1411-1413 - 12 Ulrich U, Nawroth F, Dorn C. Endometriose. Klinik, Diagnostik und Therapie.. In: Ludwig M, Hrsg. Gynäkologische Endokrinologie und Reproduktionsmedizin.. München: Hans Marseille Verlag; 2010: 219-227 - 13 Abbott J et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril. 2004; 82 878-884 - 14 Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol. 2004; 16 299-303 - 15 aaa a. DGGG .Diagnostik und Therapie der Endometriose. Available from: http://www.awmf.org 2010 - 16 Treloar S A et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol. 2010; 202 534e1-543e6 - 17 Missmer S A et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol. 2004; 104 965-974 - 18 Hediger M L, Hartnett H J, Louis G M. Association of endometriosis with body size and figure. Fertil Steril. 2005; 84 1366-1374 - 19 Parazzini F et al. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol. 1989; 18 108-112 - 20 Nouri K et al. Family incidence of endometriosis in first-, second-, and third-degree relatives: case-control study. Reprod Biol Endocrinol. 2010; 8 85 - 21 Vessey M P, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. Brit Med J. 1993; 306 182-184 - 22 Harada T et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008; 90 1583-1588 - 23 Strathy J H et al. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril. 1982; 38 667-672 - 24 Kirshon B, Poindexter 3rd A N. Contraception: a risk factor for endometriosis. Obstet Gynecol. 1988; 71 829-831 - 25 Kennedy S et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005; 20 2698-2704 - 26 Allen C et al. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005 CD004753 - 27 Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2000 2000 CD001019 - 28 Zupi E et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril. 2004; 82 1303-1308 - 29 Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs. 2004; 9 167-177 - 30 Davis L et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007 CD001019 - 31 Vercellini P et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003; 80 560-563 - 32 Proctor M L, Roberts H, Farquhar C M. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001 CD002120 - 33 Goretzlehner G. [Menstrual bleeding – must that be? Extended use of oral hormonal contraceptives]. Zentralbl Gynakol. 2005; 127 302-307 - 34 Anderson F D, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003; 68 89-96 - 35 Mahutte N G, Arici A. Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am. 2003; 30 133-150 - 36 Gomes M P, Deitcher S R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004; 164 1965-1976 - 37 Vercellini P et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010; 93 2150-2161 - 38 Prentice A, Deary A J, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000 CD002122 - 39 Luciano A A, Turksoy R N, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol. 1988; 72 323-327 - 40 Telimaa S et al. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987; 1 13-23 - 41 Schenken R. Overview of the treatment of endometriosis. Vanessa ABarss 2010 - 42 Strowitzki T et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010; 151 193-198 - 43 Seitz C, Gerlinger C, Faustmann T et al. Safety of dienogest in the long-term treatment of endometriosis: a one-year, open-label, follow-up study. Fertil Steril. 2009; 1 107 (abstract) - 44 Strowitzki T et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010; 25 633-641 - 45 Kohler G et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010; 108 21-25 - 46 Klipping C, Duijkers I, Faustmann T A et al. Pharmacodynamic study of four oral dosages of dienogest. Fertil Steril. 2010; 94 181 - 47 Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol. 2005; 17 359-365 - 48 Petta C A et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005; 20 1993-1998 - 49 Schweppe K W. [Guidelines for the use of GnRH-analogues in the treatment of endometriosis]. Zentralbl Gynakol. 2005; 127 308-313 - 50 Sagsveen M et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003 CD001297 - 51 Hornstein M D et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998; 91 16-24 - 52 Busacca M et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomized controlled trial. Hum Reprod. 2001; 16 2399-2402 - 53 Hornstein M D et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril. 1995; 63 955-962 - 54 Vercellini P et al. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol. 1999; 106 672-677 - 55 Hornstein M D et al. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril. 1997; 68 860-864 - 56 Attar E, Bulun S E. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update. 2005; 12 49-56 - 57 Ebert A D, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions – old answers?. Eur J Obstet Gynecol Reprod Biol. 2005; 122 144-150 - 58 Hughes E et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007 CD000155 - 59 Deaton J L et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril. 1990; 54 1083-1088 - 60 Tummon I S et al. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril. 1997; 68 8-12 - 61 Rickes D et al. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril. 2002; 78 757-762 - 62 Sallam H N et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006 CD004635 - 63 Donnez J et al. Large ovarian endometriomas. Hum Reprod. 1996; 11 641-646 - 64 Muzii L et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril. 1996; 65 1235-1237 - 65 Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update. 1998; 4 312-322 - 66 Fong Y F, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception. 1999; 60 173-175 - 67 Fedele L et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997; 68 426-429 - 68 Kitawaki J. Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol. 2006; 20 493-502 - 69 Bragheto A M et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007; 76 195-199 - 70 Sheng J et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009; 79 189-193 - 71 Renner S P et al. Preoperative pain and recurrence risk in patients with peritoneal endometriosis. Gynecol Endocrinol. 2010; 26 230-235 - 72 Renner S P, Oppelt P, Binder H et al. Endometriose. Geburtsh Frauenheilk. 2006; 66 R61-R88 - 73 Regidor P A et al. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol. 2001; 15 202-209 - 74 Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol. 1987; 1 363-371 - 75 Dawood M Y et al. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol. 1997; 176 387-394 - 76 Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004 CD003678 Dr. med. J. Lermann Frauenklinik der Universitätsklinik Erlangen Universitätsstraße 21–23 91054 Erlangen Email: [email protected]